C.R. Bard to license hernia product, technology from Genzyme Corp.

C.R. Bard Inc. Monday said it has entered into a license agreement with Genzyme Corp. to manufacture and market the Sepramesh IP hernia repair product line and to incorporate the related Sepra coating technology into the development of future hernia repair applications. Bard’s Davol subsidiary will begin marketing the line immediately, the companies said.

Details of the agreement were not disclosed.

Written by admin on December 20th, 2007 with no comments.
Read more articles on Hernias.